VKTX, US92686J1060

Viking Therapeutics stock: VK2735 strategy broadens after Jefferies event

Published on 11/22/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Viking Therapeutics stock gets fresh detail on VK2735 dosing and a possible 2029 launch. Management is preparing independently while remaining open to partners.

Clinical and commercial plans broaden

  • Management described weekly, every-other-week, monthly and daily oral dosing paths for VK2735.
  • Viking Therapeutics is running four Phase 3 studies, with injectable results targeted for the second half of 2027 and oral results for 2028.
  • The company is preparing for a possible 2029 launch while keeping partnership discussions open.
VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics outlined a broader clinical and commercial strategy for its obesity candidate VK2735 at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026. Investing.com reported that Chief Executive Brian Lian discussed dosing flexibility, trial milestones and preparations for a possible launch.

Flexible dosing anchors development

Viking is testing VK2735 as a weekly injection and as a daily oral treatment. Management also described every-other-week and monthly subcutaneous dosing as potential maintenance options after an initial treatment period.

The company has four Phase 3 studies underway. Lian said the first subcutaneous Phase 3 results are targeted for the second half of 2027, while results from the oral Phase 3 program are expected in 2028. The company is also running a second maintenance study that includes oral transition arms and higher-dose subcutaneous regimens.

At the conference, management cited earlier maintenance findings in which monthly dosing retained 98% of initial weight loss, with 90% of participants remaining on the monthly regimen. The company said gastrointestinal side effects eased after the titration period.

Commercial planning moves toward 2029

Viking is preparing for an independent commercial launch around 2029 while remaining open to a partnership with a larger pharmaceutical company. Management said it is evaluating direct-to-consumer, cash-pay, payer-covered and employer-based distribution channels.

The company is also advancing VK3019, an amylin candidate intended for possible standalone use or combination treatment with VK2735. A multiple-ascending-dose study is planned, with results expected toward the end of 2027.

Viking Therapeutics at a glance

  • Company: Viking Therapeutics, Inc.
  • ISIN: US92686J1060
  • Ticker: VKTX
  • Home exchange: Nasdaq
  • Business: Clinical-stage biopharmaceutical development

The broader U.S. equity market provides the relevant backdrop for the S&P 500.

More news and analyses on Viking Therapeutics stock

Disclaimer...
en | US92686J1060 | VKTX | boerse | 70544414 | bgmi